Czech Brain Ageing Study

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article reads like a press release or a news article and may be largely based on routine coverage. Please help improve this article and add independent sources. (June 2018) The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Czech Brain Ageing Study" – news · newspapers · books · scholar · JSTOR (June 2018) (Learn how and when to remove this message) This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (June 2018) This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (June 2018) (Learn how and when to remove this message) (Learn how and when to remove this message)

Czech Brain Ageing Study (CBAS) is a longitudinal, observational study on aging and dementia from two large centers in the Czech Republic combining clinical care and clinical research.

The pilot project leading to the pilot data for CBAS was established in 2005 as a longitudinal follow-up of subjects at risk of Alzheimer disease dementia (AD). A major step forward occurred in 2011 after receiving a substantial funding from the European Regional Development Fund and the Czech Ministry of Health. This funding enabled to establish the International Clinical Research Center (FNUSA-ICRC) in Brno and also enabled to synchronize the efforts in clinical and translational research between the ICRC and the Cognitive Center at Department of Neurology of the Motol University Hospital in Prague. CBAS now recruits a large numbers of participants across the two sites and is the only longitudinal study of its kind in the Czech Republic. It is also about to become the largest study to study risk factors for AD in Central and Eastern Europe.^[1]